The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
PRIMO 2023 | Increasing genomic testing for non-small cell lung cancer
Jorge Nieva, MD, University of California, San Francisco, CA, discusses the need for increased molecular profiling capabilities in patients with non-small cell lung cancer (NSCLC), which is currently inadequate. Identifying driver mutations is limited with small biopsy samples, and the availability of liquid biopsies is inconsistent. Earlier and more expedient processing of tissue samples will additionally improve genomic testing. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
